UroGen Pharma's ZUSDURI Shows Promise for At-Home Treatment of Bladder Cancer

UroGen Pharma's ZUSDURI study shows promise for at-home treatment of bladder cancer, with 75% of patients achieving complete response after six scheduled treatments. The study found that trained home health professionals could safely administer the treatment outside traditional healthcare settings. The study's small sample size and open-label design are limitations, but findings indicate that home treatment is a viable alternative to traditional clinical settings. The average target price for UroGen Pharma is $34.38, indicating an 81.40% upside from the current price of $18.95.

UroGen Pharma Ltd. (URGN) recently announced the publication of data from a Phase 3b study evaluating the feasibility of at-home instillations of ZUSDURI (mitomycin) for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC). The study, titled "Home Instillation of UGN-102 for Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Single-Arm, Open-Label, Phase 3b Trial," was published in Reviews in Urology [1].

The study demonstrated that trained home health professionals (HHPs) can safely and effectively administer ZUSDURI outside of traditional clinical settings. Seven of eight patients (87.5%) completed all six scheduled treatments, with five of those six patients indicating they would recommend the home-based approach to others. A 75% complete response (CR) rate was observed at three months (95% CI: 34.9, 96.8), and no new safety concerns were identified [2].

The study's small sample size and open-label design are limitations, but the findings indicate that home treatment is a viable alternative to traditional clinical settings. The ability to deliver this treatment safely and effectively at home has the potential to ease the burden on patients and reduce reliance on hospital or clinic resources [2].

ZUSDURI, an innovative drug formulation of mitomycin, is designed to treat adults with recurrent LG-IR-NMIBC. Utilizing UroGen's proprietary RTGel® technology, a sustained release, hydrogel-based formulation, ZUSDURI is delivered directly into the bladder in an outpatient procedure by a trained healthcare professional using a urinary catheter [2].

The average target price for UroGen Pharma is $34.38, indicating an 81.40% upside from the current price of $18.95 [1].

References:
[1] https://www.nasdaq.com/articles/urogen-pharma-publishes-phase-3b-study-data-showing-feasibility-home-instillation-zusduri
[2] https://www.globenewswire.com/news-release/2025/07/28/3122406/0/en/UroGen-Announces-Publication-of-Phase-3b-Study-Results-Demonstrating-the-Feasibility-of-Home-Instillation-of-ZUSDURI-for-Recurrent-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-B.html